GlassScriptPhysician profile
Kathleen Brunts
NPI 1851382204
$705.15
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $151 · 2021: $194.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $169.09 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $151.65 | 2019-2021 | |
| Lilly USA, LLC | $92.95 | 2019-2021 | |
| Pfizer INC. | $83.51 | 2019-2021 | |
| Amarin Pharma, INC. | $34.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.95 | 2019-2021 | |
| Allergan, INC. | $24.26 | 2019 | |
| Merck Sharp & Dohme LLC | $18.09 | 2020 | |
| Ironwood Pharmaceuticals, INC | $17.63 | 2020 | |
| Abbott Laboratories | $16.12 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.98 | 2019 | |
| Abbvie INC. | $13.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.51 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Brunts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.